Koufakis, Theocharis
Liberopoulos, Evangelos N.
Kotsa, Kalliopi
Article History
Accepted: 23 February 2022
First Online: 15 March 2022
Declarations
:
: No external funds were used in the preparation of this article.
: <i>TK</i> has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly, and Novo Nordisk and for advisory boards from Novo Nordisk, and has participated in studies sponsored by Eli-Lilly. <i>ENL</i> has participated in educational, research, and advisory activities sponsored by AstraZeneca, MSD, Lilly, Bayer, Amgen, Sanofi, Boehringer Ingelheim, Novartis, Novo Nordisk, and Servier. <i>KK</i> has received honoraria for lectures/advisory boards and research support from Astra Zeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi-Aventis, ELPEN, MSD, and Novo Nordisk.
: <i>TK</i> reviewed the literature and drafted the first version of the manuscript. <i>ENL</i> and <i>KK</i> reviewed the literature and edited the manuscript. All authors have read and approved the final version of the manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.